Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06748053 · ClinicalTrials.gov registry record · Phase 2

A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

A Phase 2 study of Asthma, sponsored by GlaxoSmithKline.

Active
Registry status
Phase 2
Development phase
307
Enrollment target
20
Study locations

NCT06748053 is a Phase 2 study of Asthma that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 307 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06748053, a Phase 2 study of Asthma, is active but no longer recruiting, sponsored by GlaxoSmithKline.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
307 participants
Enrollment target
20
Study locations

Study Summary

This study is trying to find the right dose of a long-lasting medicine called GSK5784283 for people with asthma that remains uncontrolled even though they are using regular asthma treatments. GSK5784283 blocks the action of an inflammatory protein called TSLP that may be contributing to your asthma. The study will be conducted in two parts - Part A (dose finding phase) and Part B (extended dosing phase). Part A will assess the lung function, asthma control, participant safety and certain markers of asthma inflammation in the air you breath out and in your blood. Part B will assess the safety and long-term effects of the repeated or single doses of GSK5784283.

Conditions Studied

Asthma

Interventions

  • DRUG Placebo
  • DRUG GSK5784283

Study Locations (20)

Florida

  • GSK Investigational Site - Aventura
  • GSK Investigational Site - Hialeah
  • GSK Investigational Site - Lake Worth
  • GSK Investigational Site - Leesburg
  • GSK Investigational Site - Miami
  • GSK Investigational Site - Miami
  • GSK Investigational Site - Miami
  • GSK Investigational Site - Miami
  • GSK Investigational Site - Plantation

California

  • GSK Investigational Site - Long Beach
  • GSK Investigational Site - Los Angeles
  • GSK Investigational Site - Redding
  • GSK Investigational Site - Riverside
  • GSK Investigational Site - Sacramento
  • GSK Investigational Site - San Jose

Colorado

  • GSK Investigational Site - Colorado Springs
  • GSK Investigational Site - Lakewood
  • GSK Investigational Site - Wheat Ridge

Arkansas

  • GSK Investigational Site - Little Rock

Connecticut

  • GSK Investigational Site - New Haven

Trial Details

FieldValue
Enrollment Target 307 participants
Start Date 2025-02-10
Est. Completion 2027-09-09
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06748053

The ClinicalTrials.gov registry entry for NCT06748053 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 307 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (80% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06748053 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT06748053 about?

NCT06748053 is a clinical study titled "A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma". This study is trying to find the right dose of a long-lasting medicine called GSK5784283 for people with asthma that remains uncontrolled even though they are using regular asthma treatments. GSK5784283 blocks the action of an inflammatory protein called TSLP that may be contributing to your asthma....

What is the current status of trial NCT06748053?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 307 participants. The study started on 2025-02-10. Estimated completion is 2027-09-09.

What conditions does trial NCT06748053 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT06748053?

The interventions under investigation include: Placebo (DRUG), GSK5784283 (DRUG).

Who is sponsoring clinical trial NCT06748053?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06748053 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Asthma

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.